The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL sol from CDSO.

The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages (SMAs).

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.

Astrazeneca Pharma India has received CDSO's (Central Drugs Standard Control Organisation) nod for the import of Durvalumab for its sale and distribution.

Bengaluru: AstraZeneca Pharma India Limited has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion from the Central

AstraZeneca Pharma India has received approval from the CDSO for the import, sale, and distribution of Durvalumab.

This approval allows Durvalumab to be used together with chemotherapy before surgery, and then as a single treatment afterward.

Key Takeaways A breast cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer than with chemotherapy in a phase 3 trial.The trial included over 700 patients with inoperable or metastatic breast cancer.

The approved indication involves using durvalumab in combination with chemotherapy as a neoadjuvant treatment, followed by durvalumab monotherapy post-surgery. Shares of Astrazeneca Pharma India Ltd ended at ₹6,